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It is a well-established fact that transgender people often face difficulty 
in accessing healthcare[1] – both gender-affirming as well as general 
healthcare. As a marginalised group, transgender people are already 
at a higher risk of suicide than the general population, in addition to 
being more likely to be unemployed or have a low income, and more 
likely to suffer sexual or physical assault.[1] 
A 2015 Canadian study suggested that among intervenable factors 
that can reduce suicide risk among transgender populations, access 
to medical transition (i.e. gender-affirming care) was a significant role-
player.[2,3 ]
Furthermore, multiple studies exist to suggest that gender-affirming 
hormonal intervention in transgender people can be considered as 
generally safe, and is associated with minimal side-effects, morbidity 
or increases in mortality.[4,5]
Despite these data that point towards access to gender-affirming care 
not only being safe, but also playing a significant role in reducing suicide 
risk in transgender people, there are still difficulties in accessing this care. 
A small study of 101 assigned-male-at-birth (AMAB) transgender people 
in New York City enumerated some of the most prominent barriers to 
accessing care as a lack of knowledge among service providers, a paucity 
of transgender-friendly providers and cost.[6] Focus groups in Boston 
comprising both adults and youth – and both AMAB and assigned-
female-at-birth (AFAB) patients – yielded similar results.[7]
The fundamentals of medical ethics
Beauchamp and Childress,[8] in Principles of Medical Ethics, first 
published in 1979, posited four basic ethical principles applicable to 
medical practice; although the specifics of actually applying these 
principles need to be considered on an individual case-by-case 
basis, and the framework itself is not flawless,[9] these principles are 
widely accepted and taught in medical schools across the globe as a 
framework for decision-making.
The four ‘pillars’ of medical ethics are as follows:[8,9]
(i) Respect for autonomy: this principle provides the basis for 
‘informed consent’, recognising the patient as an independent agent 
with the capacity and right to make their own decisions with respect 
to their healthcare and bodies.
(ii) Non-maleficence: this principle imposes a requirement on the 
healthcare provider not to intentionally cause injury or harm to the 
patient, be it through commission or omission of an act.
(iii) Beneficence: the principle of beneficence establishes a 
responsibility on the provider to act in ways that are of benefit to 
the patient.
(iv) Justice: this is a complex and sometimes difficult-to-navigate 
principle that requires providers to distribute resources in ways that 
are fair and equitable, particularly in situations where resources are 
limited. 
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Introduction. For many transgender patients, access to healthcare – and specifically gender-affirming care (such as hormone replacement 
therapy) – is limited by a variety of different barriers. Despite evidence showing that access to medical transition is not only safe, but also 
improves suicide risk in transgender patients, these services are often subject to excessive gatekeeping by medical professionals and 
healthcare workers.
Objectives. To evaluate the ethical merits of the two most prominent models of providing gender-affirming care to patients who identify 
as transgender.
Methods. The author compares the gatekeeping model and the informed consent model of providing gender-affirming care, in terms of the 
well-recognised four fundamental ‘pillars’ of medical ethics, namely respect for autonomy, non-maleficence, beneficence and distributive justice.
Results. The gatekeeping model is found to be in violation of all four principles, while an informed consent model of care respects these 
ethical pillars.
Discussion. A variety of ethical factors are at play in the provision of gender-affirming care to transgender patients, and these need to be 
considered carefully in formulating approaches or models. There are many other factors that can present a barrier to gender-affirming care in 
a South African context, but an examination of the ethical considerations can be of immediate benefit to an already marginalised population.
Conclusion. Clinicians should be aware of the ethical factors in withholding gender-affirming care from transgender patients, and the 
potential consequences thereof. An approach based on a model of informed consent, which respects a patient’s agency over their own body, 
is both clinically safe and ethically sound.
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History of gatekeeping access to gender-
affirming care
For many years, the Harry Benjamin International Gender Dysphoria 
Association has provided guidelines, standards and recommendations 
on the requirements for initiating gender-affirming care in 
transgender patients. The organisation, named after endocrinologist 
Harry Benjamin, one of the first physicians who worked with 
transgender patients, has subsequently been renamed as the World 
Professional Association for Transgender Health (WPATH), and 
continues to publish guidelines as the Standards of Care for the Health 
of Transsexual, Transgender, and Gender Nonconforming People (SOC).
The most recent iteration of the SOC is Version 7, released in 2011. 
The document was first published in 1979; prior to the release of 
the 7th edition, the most recent update to the SOC was published 
in 2001.[10]
According to the 2001 version of the SOC, in order to be eligible 
for gender-affirming hormonal interventions, adult patients needed 
to fulfil the following requirements (a separate set of requirements 
is suggested for younger patients, though this is beyond the scope 
of this article):
‘1. be of at least 18 years of age.
2. possess demonstrable knowledge of the medical effects and 
limitations of hormones, as well as the social benefits and risks thereof.
3. have had either: a) a documented real-life experience (RLE) of at 
least 3 months; or b) a period of psychotherapy of a duration specified 
by the mental health practitioner (usually a minimum of 3 months).’
In addition to these eligibility criteria, a further set of ‘readiness 
criteria’ are imposed:
‘1. The patient has had further consolidation of the patient’s gender 
identity during RLE or psychotherapy
2. The patient has made some progress in mastering other identified 
problems, leading to improving or continuing stable mental health 
(this implies satisfactory control of problems such as sociopathy, 
substance abuse, psychosis or suicidality).
3. The patient is likely to take hormones in a responsible manner.’
A concession is made for patients who do not fulfil readiness 
criterion 3, in instances where the patient is likely to use black-market 
hormone therapy, as a means of harm reduction.
Although the document itself introduces these standards of care 
as ‘flexible directions’, they came to be widely known and adopted by 
healthcare providers – specifically, the requirements of psychotherapy 
and RLE. Consequently, these requirements have been the subject of 
criticism by activists and mental healthcare practitioners alike.[11,12]
The document goes on to refer to the RLE as the ‘ultimate diagnosis’ 
of transgender identity, and suggests that based on the RLE, patients 
might decide that transition is ‘not in their best interest’. In fact, 
detransition and rates of ‘transition regret’ are known to be very low, 
even after surgery – depending on the study cited, this rate varies 
from as little as 0% to a maximum of 4%, significantly lower than 
regret rates in cisgender patients following elective plastic surgery 
procedures.[13-15]
Also worth noting is that the document positions the clinician as 
the ultimate assessor of whether the RLE is ‘successful’. As part of this 
assessment, the patient must prove sufficiently able:
‘1. to maintain full or part-time employment
2. to function as a student
3. to function in community-based volunteer activity
4. to undertake some combination of items 1 - 3
5. to acquire a (legal) gender-identity-appropriate first name
6. to provide documentation that persons other than the therapist 
        know that the patient functions in the desired gender role.’
Although these requirements are problematic for many different 
reasons, three stand out to this author as especially significant:
(i) the subjectivity of assessing whether or not the patient is able 
‘to function’
(ii) the imposition of cis-normative standards in determining 
whether a first name is ‘gender-identity-appropriate’
(iii) the requirement of a patient to ‘out’ themselves to others as a 
requirement for intervention.
There are many other difficulties that can be raised with RLE, in 
terms of intersectional feminism and queer theory; those arguments, 
however, are beyond the scope of this paper. 
Informed consent as the basis for gender-
affirming care
As already discussed, WPATH’s SOC is currently in its 7th iteration. 
Published in 2011, the SOC Version 7 introduces significant changes to 
the guidelines. According to WPATH, the document has been created 
on the basis of the best available science and expert professional 
consensus, and Version 7 represents a ‘significant departure from 
previous versions … based upon significant cultural shifts, advances 
in clinical knowledge and appreciation of the many healthcare issues 
that can arise for transsexual, transgender, and gender nonconforming 
people beyond hormone therapy and surgery’.[16]
The current edition of the SOC requires that healthcare providers 
educate their patients or clients not just on the diversity of gender 
identities and expressions, but also on the various options available 
for managing gender dysphoria. It is the responsibility of the 
provider to prepare the patient to make a fully informed decision 
regarding treatment options. 
Furthermore, the document goes on to state that ‘decisions about 
hormones are first and foremost the client’s decisions – as are all 
decisions regarding healthcare,’ a significant change in position 
from previous versions of these guidelines, and an important 
assertion that prioritises the patient’s agency and autonomy.
Psychotherapy, although recommended, is explicitly stated not to 
be an absolute requirement for hormone therapy. The document also 
asserts that its suggestions are in line with the informed-consent 
models of treatment employed at such renowned centres for 
transgender healthcare as Callen-Lorde and Fenway Health.
According to WPATH, the current criteria for eligibility for hormone 
therapy in transgender individuals are as follows:
1. persistent, well-documented gender dysphoria
2. the capacity to make a fully informed decision and to consent 
for treatment
3. having reached the age of majority in a given country
4. reasonably well-controlled medical or mental health concerns, 
if present and significant.
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It is particularly important to note that RLE is no longer listed in these 
criteria, although many service providers still assume that it is, and 
insist on it as a requirement.
Furthermore, the purpose of the document as a flexible guideline 
is reinforced, and acknowledgment granted to the notion that in 
certain cases, one or more of these criteria may be waived, again 
citing harm reduction (such as preventing the use of black-market 
hormones) as an example of when this might be done.
It should also be noted that, as outlined in criterion 4 above, the 
presence of comorbid mental health conditions should be managed 
appropriately. Such conditions, however, should not preclude access 
to gender-affirming care, unless they interfere with an individual’s 
capacity to make an informed decision.
Comparison of gatekeeping and informed 
consent within the framework of medical 
ethics
Despite the support of WPATH, the Callen-Lorde Community Health 
Center and Fenway Community Health for an informed consent 
model of treatment,[16-18] gatekeeping remains a pervasive barrier to 
accessing care for transgender people.[19-22]
In light of this, the author believes that it might be of benefit 
to compare these two models of gender-affirming care, namely 
gatekeeping and informed consent, within the already-introduced 
framework of medical ethics.
Respect for autonomy
The argument in terms of this principle is straightforward and 
virtually self-explanatory. If access to care is gatekept by service 
providers – that is to say, if the healthcare provider makes the 
assessment of whether or not a patient should be allowed access to 
gender-affirming care – this is a blatant violation of the principle of 
respect for autonomy.
In contrast, an informed consent model preserves the integrity of 
this ethical principle by empowering a patient to make their own 
decision with regard to their healthcare.
Non-maleficence
A gatekeeping approach to gender-affirming care is founded on 
the idea that hormonal therapy may be harmful to patients – either 
directly, through the biological and chemical consequences of such 
treatment, or because of the ‘social risks’, or the fear that patients will 
regret their decision to pursue medical transition.
Although gender-affirming hormonal intervention is not without 
side-effects, these side-effects are well established, and are outlined 
comprehensively in the SOC. Furthermore, many of these side-
effects (for example, the cessation of menses in AFAB patients) might 
be regarded as beneficial rather than detrimental in the case of 
transgender individuals. 
As already established, hormonal therapy in transgender patients 
has been demonstrated scientifically to be safe.[4,5] Furthermore, it 
is known that many of the irreversible effects of hormone therapy 
take significant periods of time to develop – notably: breast growth 
(onset 3 - 6 months; maximal effect 2 - 3 years) in AMAB patients, 
and scalp hair loss (onset <12 months; maximal effect variable), 
clitoral enlargement (onset 3 - 6 months; maximal effect 1 - 2 years), 
deepened voice (onset 3 - 12 months; maximal effect 1 - 2 years) and 
facial hair growth (onset 3 - 6 months; maximal effect 3 - 5 years) in 
AFAB patients.[16,23-25]
Therefore, it is established that these consequences – which are 
often not viewed by patients as deleterious – take time to develop; 
they are not instantaneous. Furthermore, there are interventions 
available should these effects later be viewed by the patient as 
undesirable – for example, surgical removal of breast tissue, or laser 
hair removal for unwanted facial hair. 
Given the length of time needed for these changes to develop to 
any noteworthy extent, and acknowledging that although cessation 
of hormone therapy alone will not reverse these changes, there are 
other means by which they may be reversed, it seems fair to argue 
that non-maleficence is not a valid justification to gatekeep access to 
gender-affirming care.
As clinicians, we strive to act with our patients’ best interests at 
heart, and that can lead to a tendency to try to ‘protect patients 
from themselves’, which, in this instance, may be motivated by fear 
of the effects or consequences of gender-affirming care. Two points 
are important to note here. Firstly, although there are side-effects 
associated with gender-affirming care, we should not neglect the 
fact that exposure to endogenous hormones for transgender persons 
is also not without deleterious (and often irreversible) effects; these 
should not be neglected when considering what is in a patient’s 
best interests. Secondly, bearing in mind the principle of respect 
for autonomy already discussed, it should be reiterated that the 
practitioner’s responsibility is to inform the patient of potential 
risks or side-effects, and to assess the patient’s capacity to make an 
informed decision,[26] without letting personal preconceptions or 
misgivings influence this process.
Furthermore, it can be argued that since access to medical transition 
improves outcomes (particularly suicide risk) for transgender 
patients,[2,3] limiting access to these interventions can be seen as 
harmful in and of itself, and as such, is a violation of the principle of 
non-maleficence.
Conversely, an informed consent model of treatment that educates 
patients as to the risks of hormone therapy, as well as the benefits, 
and allows them to make a decision on their own can hardly be 
viewed as harmful, given that we have already established the safety 
of hormonal interventions.
Beneficence
The discussion around beneficence is closely related to the points 
already outlined in discussing non-maleficence, and so the discourse 
that follows will be brief. Recognising that gatekeeping is cited as a 
barrier to accessing care, and that the inability to access care is in fact 
deleterious to transgender patients, it becomes difficult to reconcile 
such a practice with the principle of beneficence.
In contrast, by respecting, validating and affirming a patient’s 
identity, and their right to make their own decisions regarding their 
healthcare and treatment, we are directly improving outcomes for 
patients – there are numerous studies that show improved quality 
of life and outcomes in transgender patients following interventions 
such as hormone therapy and surgery.[2,27,28] As such, the informed 
consent approach to treatment is respectful of the ethical principle 
of beneficence.
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Justice
Within the gatekeeping model of access to care, it is the healthcare 
provider or clinician who ultimately assesses whether or not a patient 
will gain access to healthcare. These assessments might be made 
on several different grounds, but in accordance with the guidelines 
posited by editions of SOC[10] earlier than version 7, they are usually 
contingent on either (i) the ‘success’ of the RLE, and/or (ii) a period of 
psychotherapy.
‘Success’ in terms of RLE is defined as the ability of the patient to 
‘prosper in the preferred gender’, in terms of the patient’s resolve, and 
their capacity to function in that gender, as well as the adequacy of 
social, economic and psychological supports.
It is not difficult to understand that this is a flawed metric, for a 
number of reasons. Much of the ‘assessment’ is contingent not on the 
patient’s actual experience, but rather on how the patient is seen by 
outside observers – specifically the clinician or provider, but also the 
rest of society.
Firstly, for patients who identify outside of the gender-binary, 
how is ‘success’ defined? There is no established objective metric for 
‘capacity to function’ in a gender; by definition, it is subjective, and 
patients with a non-binary identity are, from the outset, prejudiced 
in this assessment, as their experiences lie outside of cultural and 
societal norms.
Secondly, the guidelines themselves suggest that this assessment 
is contingent on the ‘adequacy of social, economic and psychological 
supports’; therefore, a patient who is financially secure, for example, 
fulfils this criterion, whereas one who is economically disadvantaged 
might not.
To illustrate: consider two hypothetical transgender patients. The 
first patient, Sue, is AMAB, with a female gender identity, white, 
college-educated and gainfully employed. Sue is 5’7” tall and has a 
slight frame. She does not have thick facial or body hair, but anyway 
can afford laser hair removal, regular waxing, skin treatments, a 
wardrobe of flattering clothes and expensive makeup.
The second patient, Jo, is AMAB, with a female gender identity, 
is a person of colour, has a disadvantaged background, lives in a 
rural area and works a minimum-wage job. She is 6’3” tall, has broad 
shoulders and heavy bone structure, and dense facial and body hair. 
She cannot afford cosmetic treatments or products, and has only her 
old masculine clothes in her wardrobe.
Of these two patients, who is likely to be more ‘successful’ in the 
RLE? Almost certainly, Sue will have an easier time – she is likely 
to face less discrimination and prejudice, and has better access to 
resources, including psychotherapy. This is especially significant 
in the absence of hormonal intervention – which promotes the 
development of physical features that are concordant with an 
individual’s gender identity.
In the example scenario, the patient who has better resources, 
and a more ‘fortunate’ genetic profile, is more likely to gain access to 
gender-affirming care. 
Certainly, this is a blatant violation of the ethical principle of 
distributive justice.
(It should be noted that there is potential to discuss the implications 
and ramifications of what constitutes ‘successful’ RLE in terms of 
gender theory, with particular attention given to the concept of 
‘passing’, and the distinction between gender identity and expression, 
but again that is beyond the scope of this article – for the purposes 
of this discussion, it is assumed that these assessments are made 
according to binary and cis-normative standards, which themselves 
are flawed.)
An informed consent approach, conversely, promotes equity and 
fairness by allowing patients to decide on their own healthcare, 
without subjecting them to restrictions based on factors that are 
beyond their control. By refusing to prejudice a patient’s right to access 
care based on such factors as race, social class, finances or genetics, we 
respect and maintain the integrity of the principle of justice.
Conclusion
In conclusion, there are several points that should be taken into 
account when evaluating approaches to initiating gender-affirming 
care in transgender patients.
It is important to recognise that there is a growing body of evidence 
to suggest that hormonal therapy in transgender patients is safe, and 
is not associated with increases in morbidity or mortality. Furthermore, 
there is also evidence suggesting that access to gender-affirming care 
is an important intervenable factor that can significantly reduce suicide 
risk in what is known to be a vulnerable population.
In addition, many renowned clinics and expert groups have 
led by example in distancing themselves from such practices as 
gatekeeping, opting rather to treat patients in accordance with an 
informed consent model of treatment. It is not without relevance to 
acknowledge that WPATH, at the time known as the Harry Benjamin 
Gender Dysphoria Association, was once the most significant 
proponent of a gatekeeping model of gender-affirming care, and 
has recognised the problems inherent in such a model. In response 
to this recognition, WPATH now advocates for an informed consent 
approach that is consistent with the model employed by leading 
gender clinics.
Being cognisant of these developments, and examining the two 
differing approaches to gender-affirming care within a framework 
of medical ethics, based upon Beauchamp and Childress’[8] well-
recognised four pillars of medical ethics, it can be demonstrated that 
a gatekeeping model of care is found to be in violation of all four 
principles: autonomy, non-maleficence, beneficence and justice.
In stark contrast, an approach based on the principles of informed 
consent preserves the integrity of these pillars of medical ethics. 
It should, of course, be noted that there remain additional obstacles 
to accessing gender affirming care – such as costs of treatment, 
competence of providers, and social circumstances, among others – 
but overcoming these barriers involves a separate, and far lengthier, 
discussion. Moving towards an informed consent model of care is 
not a silver bullet that solves all problems when considering gender-
affirming care, but it is nonetheless a significant step, and one that is 
ethically sound. 
The author therefore concludes that any approach to gender-
affirming care that utilises gatekeeping, particularly in the form of 
enforced RLE or psychotherapy, should be regarded as unethical, and 
that clinicians should be aware of this when managing or interacting 
with transgender patients.
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